Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors
Conditions
Interventions
DB-1305/BNT325
Pembrolizumab
+1 more
Locations
30
United States
Site 103
Cerritos, California, United States
Site 108
Los Angeles, California, United States
D&H Cancer Research Center Llc
Margate, Florida, United States
Site 109
Plantation, Florida, United States
BRCR Medical Center Inc.
Tamarac, Florida, United States
Site 106
Detroit, Michigan, United States
Start Date
July 19, 2022
Primary Completion Date
June 30, 2025
Completion Date
June 30, 2025
Last Updated
February 27, 2025
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
DualityBio Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions